Yang, Xiefeng
Hu, Chengcong
Xing, Zhen
Lin, Yu
Su, Yan
Wang, Xingfu
Cao, Dairong http://orcid.org/0000-0002-0051-3143
Funding for this research was provided by:
The National Natural Science Foundation of China (82071869)
Fujian Provincial Health Technology Project (2021QNB006)
The Leading Project of the Department of Science and Technology of Fujian Province (2020Y0025)
Joint Funds for the Innovation of Science and Technology, Fujian Province (2021Y9154)
Article History
Received: 3 September 2022
Revised: 19 February 2023
Accepted: 9 March 2023
First Online: 3 May 2023
Declarations
:
: The scientific guarantor of this publication is Dairong Cao.
: The authors of this manuscript declare no relationships with any companies, whose products or services may be related to the subject matter of the article.
: No complex statistical methods were necessary for this paper.
: Written informed consent was waived by the Institutional Review Board.
: Institutional Review Board approval was obtained.
: Some patients in the present study cohort overlapped with one of our studies which is now published online (ExternalRef removed), in which we used diffusion, susceptibility, and perfusion-weighted imaging to grade IDH mutant astrocytoma. As for the advanced MRI part, 107 cases (78.6%) overlapped in these two studies. In the present study, we used conventional MRI, SWI, DWI, and DSC-PWI to predict Ki-67 Labeling Index, ATRX Mutation, and MGMT Promoter Methylation Status, which is far different from our previous study.
: UnorderedList removed